Teva Neuroscience, Inc. (TEVA) Release: Recently Published Clinical Pharmacology Study Confirms Azilect(R) Selectively Inhibits MAO-B at Approved Doses
6/2/2010 10:29:12 AM
KANSAS CITY, Mo.--(BUSINESS WIRE)--Teva Neuroscience Inc. today announced the publication of a study demonstrating the selectivity of Azilect® (rasagiline tablets) for inhibition of MAO-B (monoamine oxidase-B) at the maximum approved dose of 1 mg/day. The data was published in the Journal of Clinical Pharmacology OnlineFirst on May 5, 2010.
comments powered by